Table 1.
Participant demographics, pre-existing health conditions, prior hospitalization, and EBV serology results by Long COVID definitions including participant with sample time points greater than 60 days after initial infection.
| All Participants | No Long COVID | Long COVID | LC >5 Symptoms | |
|---|---|---|---|---|
| N (% of all participants) | 280a | 72 (25.7) | 208 (74.2) | 97 (34.6) |
| Timing in days of data collection following acute COVID symptom onset [median (QR)]b | 123 (114, 134) | 124 (116, 132) | 123 (112, 135) | 123 (109, 145) |
| Age [median (QR)] | 45 (36, 56) | 44 (32, 54) | 46 (36, 56) | 45 (35, 56) |
| Male Sex [n (column %)]b | 156 (55.7) | 42 (58.3) | 114 (54.8) | 46 (47.4) |
| BMI >30 [n (%)] | 177 (64.6) | 40 (58.8) | 137 (66.5) | 67 (70.5) |
| Pre-existing Health Condition [n (%)] | ||||
| Autoimmune Disease | 18 (6.4) | 3 (4.2) | 15 (7.2) | 7 (7.2) |
| Diabetes | 25 (9.1) | 7 (9.7) | 18 (8.9) | 12 (12.8) |
| Heart Disease | 8 (2.9) | 3 (4.2) | 5 (2.4) | 3 (3.2) |
| Hypertension | 53 (19.1) | 11 (15.5) | 42 (20.4) | 21 (22.1) |
| Lung Disease | 48 (17.3) | 11 (15.5) | 37 (18.0) | 20 (21.1) |
| Hospitalized [n (%)] | 49 (17.9) | 6 (8.8) | 43 (20.9) * | 25 (26.0) ** |
| HIV [n (%)] | 54 (19.3) | 12 (16.7) | 42 (20.2) | 21 (21.6) |
| EBV Serologyd [n (%)] | ||||
| EBV VCA IgG+ | 259 (94.9) | 64 (92.8) | 195 (95.6) | 90 (94.7) |
| EBV VCA IgG >750 | 105 (38.5) | 28 (40.6) | 77 (37.7) | 36 (37.9) |
| EBV VCA IgM+ | 10 (3.7) | 2 (2.9) | 8 (3.9) | 2 (2.1) |
| EBV NA IgG+ | 243 (89.0) | 61 (88.4) | 182 (89.2) | 84 (88.4) |
| EBV NA IgG >600 U/mL | 110 (40.0) | 19 (27.5) | 91 (44.6) * | 45 (47.4) * |
| EBV EA-D IgG+ | 98 (35.9) | 23 (33.3) | 75 (36.8) | 39 (41.1) |
| CMV IgG+ | 153 (54.8) | 42 (58.3) | 111 (53.6) | 51 (52.6) |
BMI = body mass index; EBV = Epstein Barr Virus; VCA = viral capsid antigen; NA = anti-nuclear antigen; EA-D = anti-early antigen D
Variables with missing data (missing N): BMI (6), diabetes (6), heart disease (4), hypertension (3), lung disease (3), hospitalized (5), EBV antibody results (7), CMV results (1)
QR = 25%, 75% quartiles
n = number of participants with underlying condition or positive laboratory results, % = percent within column
Plasma EBV DNA was tested in a subgroup of 50 participants; one participant with one PASC symptom had detectable DNA below the limit of quantitation (<390 copies/mL)
P <0.05,
P <0.01 by two-tailed Chi Square Testing or Fisher Exact Test if any expected value <5 for data comparing PASC >5 symptoms or All LC to no LC